These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15001452)

  • 1. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
    Sidhu JS; Kaposzta Z; Markus HS; Kaski JC
    Arterioscler Thromb Vasc Biol; 2004 May; 24(5):930-4. PubMed ID: 15001452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
    Sidhu JS; Cowan D; Kaski JC
    J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
    Sidhu JS; Cowan D; Tooze JA; Kaski JC
    Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
    Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
    Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
    Yee MS; Pavitt DV; Dhanjil S; Godsland IF; Richmond W; Johnston DG
    Diabet Med; 2010 Dec; 27(12):1392-400. PubMed ID: 21059092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
    Taylor AJ; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Circulation; 2004 Dec; 110(23):3512-7. PubMed ID: 15537681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
    Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
    J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
    Marx N; Imhof A; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Maerz W; Hombach V; Koenig W
    Circulation; 2003 Apr; 107(15):1954-7. PubMed ID: 12695287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relation of the thickness of the intima and media of the common carotid artery, atherosclerotic plaque in the carotids and manifestations of atherosclerosis in the vessels of the lower extremity in comparison to coronary atherosclerosis].
    Holaj R; Spácil J; Petrásek J; Malík J; Aschermann M; Haas T
    Cas Lek Cesk; 1998 Nov; 137(23):716-20. PubMed ID: 9990175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intima-media thickness of the carotid arteries in subjects with hyperinsulinaemia (insulin resistance).
    Hidvégi T; Szatmári F; Hetyési K; Bíró L; Jermendy G
    Diabetes Nutr Metab; 2003 Jun; 16(3):139-44. PubMed ID: 14635730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
    Varghese A; Yee MS; Chan CF; Crowe LA; Keenan NG; Johnston DG; Pennell DJ
    J Cardiovasc Magn Reson; 2009 Jul; 11(1):24. PubMed ID: 19635160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study.
    Duman D; Demirtunc R; Sahin S; Esertas K
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1007-11. PubMed ID: 18163011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease.
    Granér M; Varpula M; Kahri J; Salonen RM; Nyyssönen K; Nieminen MS; Taskinen MR; Syvänne M
    Am J Cardiol; 2006 Mar; 97(5):624-9. PubMed ID: 16490425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis.
    Kumeda Y; Inaba M; Goto H; Nagata M; Henmi Y; Furumitsu Y; Ishimura E; Inui K; Yutani Y; Miki T; Shoji T; Nishizawa Y
    Arthritis Rheum; 2002 Jun; 46(6):1489-97. PubMed ID: 12115178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study).
    Haffner SM; Agostino RD; Saad MF; O'Leary DH; Savage PJ; Rewers M; Selby J; Bergman RN; Mykkänen L
    Am J Cardiol; 2000 Jun; 85(12):1395-400. PubMed ID: 10856382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2.
    Fateh-Moghadam S; Li Z; Ersel S; Reuter T; Htun P; Plöckinger U; Bocksch W; Dietz R; Gawaz M
    Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1299-303. PubMed ID: 15817881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
    Hodis HN; Mack WJ; Zheng L; Li Y; Torres M; Sevilla D; Stewart Y; Hollen B; Garcia K; Alaupovic P; Buchanan TA
    Diabetes Care; 2006 Jul; 29(7):1545-53. PubMed ID: 16801577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.